Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis - PubMed (original) (raw)
Meta-Analysis
Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis
Jeremy G Wheeler et al. PLoS Med. 2005 Mar.
Abstract
Background: It has been suggested throughout the past fifty years that serum uric acid concentrations can help predict the future risk of coronary heart disease (CHD), but the epidemiological evidence is uncertain.
Methods and findings: We report a "nested" case-control comparison within a prospective study in Reykjavik, Iceland, using baseline values of serum uric acid in 2,456 incident CHD cases and in 3,962 age- and sex-matched controls, plus paired serum uric acid measurements taken at baseline and, on average, 12 y later in 379 participants. In addition, we conducted a meta-analysis of 15 other prospective studies in eight countries conducted in essentially general populations. Compared with individuals in the bottom third of baseline measurements of serum uric acid in the Reykjavik study, those in the top third had an age- and sex-adjusted odds ratio for CHD of 1.39 (95% confidence interval [CI], 1.23-1.58) which fell to 1.12 (CI, 0.97-1.30) after adjustment for smoking and other established risk factors. Overall, in a combined analysis of 9,458 cases and 155,084 controls in all 16 relevant prospective studies, the odds ratio was 1.13 (CI, 1.07-1.20), but it was only 1.02 (CI, 0.91-1.14) in the eight studies with more complete adjustment for possible confounders.
Conclusions: Measurement of serum uric acid levels is unlikely to enhance usefully the prediction of CHD, and this factor is unlikely to be a major determinant of the disease in general populations.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
JD is a member of the editorial board of PLOS Medicine.
Figures
Figure 1. Associations between Serum Uric Acid and CHD in 2,456 cases and 3,962 Controls in the Reykjavik Study at Different Levels of Established Risk Factors
Squares indicate odds ratios, with the size of the square proportional to the effective sample size.
Figure 2. Meta-Analysis of Prospective Observational Studies of Serum Uric Acid and CHD in Essentially General Populations, Subdivided by Sex
Conventions are the same as in Figure 1. Combined odds ratios and their CIs are indicated by unshaded diamonds for subtotals and shaded diamonds for grand totals. +, adjustment reported only for age and sex; ++, adjustment for these plus smoking; +++, adjustment for these plus some additional established risk factors; ++++, adjustment for these plus existing cardiovascular disease. Study abbreviations: ARIC, Atherosclerosis Risk in Communities; BIRNH, Belgium Interuniversity Research on Nutrition and Health; BRHS, British Regional Heart Study; CHA, Chicago Heart Association Detection Project in Industry; GRIPS, Göttingen Risk Incidence and Prevalence Study; IIHDS, Israeli Ischemic Heart Disease Study; MONICA, World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease; NHANES, National Health and Nutrition Examination Survey; NHEFS, NHANES I Epidemiologic Follow-Up Study; PROCAM, Prospective Cardiovascular Munster Study.
Figure 3. Prospective Studies of the Association of Serum Uric Acid and CHD, Grouped by Various Characteristics
Conventions are the same as in Figure 1. *, each sex-specific estimate was treated as a “study”; †, two studies (6 and 13) were drawn from general practice registers; §, risk factors adjusted for included: smoking, blood pressure, total cholesterol, triglycerides, alcohol consumption, obesity, use of cardiovascular medication, history of hypertension, and history of diabetes. PTA, phosphotungstic acid.
Similar articles
- Serum uric acid is a determinant of metabolic syndrome in a population-based study.
Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Sari I, Yazici M, Keleş I. Onat A, et al. Am J Hypertens. 2006 Oct;19(10):1055-62. doi: 10.1016/j.amjhyper.2006.02.014. Am J Hypertens. 2006. PMID: 17027827 - C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. Danesh J, et al. N Engl J Med. 2004 Apr 1;350(14):1387-97. doi: 10.1056/NEJMoa032804. N Engl J Med. 2004. PMID: 15070788 - Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis.
Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Lowe GD, et al. Eur Heart J. 2004 Feb;25(3):252-9. doi: 10.1016/j.ehj.2003.11.004. Eur Heart J. 2004. PMID: 14972427 - Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies.
Sarwar N, Sattar N, Gudnason V, Danesh J. Sarwar N, et al. Eur Heart J. 2007 Oct;28(20):2491-7. doi: 10.1093/eurheartj/ehm115. Epub 2007 May 17. Eur Heart J. 2007. PMID: 17513304 Review.
Cited by
- Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Yen FS, et al. PLoS One. 2020 Jun 23;15(6):e0234909. doi: 10.1371/journal.pone.0234909. eCollection 2020. PLoS One. 2020. PMID: 32574194 Free PMC article. - Urate as a predictor of the rate of clinical decline in Parkinson disease.
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators. Ascherio A, et al. Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Arch Neurol. 2009. PMID: 19822770 Free PMC article. Clinical Trial. - Uric Acid Contributes to Obesity-Paradox of the Outcome of Ischemic Stroke.
Tang H, Mo J, Chen Z, Xu J, Wang A, Dai L, Cheng A, Wang Y. Tang H, et al. Front Neurol. 2019 Dec 5;10:1279. doi: 10.3389/fneur.2019.01279. eCollection 2019. Front Neurol. 2019. PMID: 31866932 Free PMC article. - Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Kim SY, et al. Arthritis Care Res (Hoboken). 2010 Feb;62(2):170-80. doi: 10.1002/acr.20065. Arthritis Care Res (Hoboken). 2010. PMID: 20191515 Free PMC article. Review. - Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?
Krajčoviechová A, Wohlfahrt P, Bruthans J, Šulc P, Lánská V, Eremiášová L, Pudil J, Linhart A, Filipovský J, Mayer O, Widimský J, Blaha M, Borghi C, Cífková R. Krajčoviechová A, et al. J Clin Hypertens (Greenwich). 2020 May;22(5):897-905. doi: 10.1111/jch.13847. Epub 2020 Apr 9. J Clin Hypertens (Greenwich). 2020. PMID: 32271996 Free PMC article.
References
- Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14:615–631. - PubMed
- Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34:1421–1431. - PubMed
- Rich MW. Uric acid: Is it a risk factor for cardiovascular disease? Am J Cardiol. 2000;85:1018–1021. - PubMed
- Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekelle RB, et al. Uric acid: A risk factor for coronary heart disease? Circulation. 1979;59:969–977. - PubMed
- Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiological Follow-up Study. Am J Epidemiol. 1995;141:637–644. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous